How to compare at‑home allergy care in 2026

Telehealth allergy clinics all deliver “SLIT” (sublingual immunotherapy) from home, but they differ on medical oversight, which SLIT they use (drops vs. FDA‑approved tablets), pricing, and insurance handling. This guide explains the clinical methods and shows verified pricing so you can compare Wyndly, Curex, Nectar, and in‑clinic options for 2026.

What SLIT actually is (and what the FDA has approved)

• SLIT is immunotherapy given under the tongue to retrain the immune system. In the United States, the FDA has approved only sublingual tablets for specific allergens: grass (Grastek, Oralair), ragweed (Ragwitek), and dust mite (Odactra). The first dose is observed in a clinician’s office, then daily dosing continues at home with an epinephrine auto‑injector on hand. Allergy “drops” are compounded, off‑label in the U.S. (widely used, but not FDA‑approved). [Sources: FDA; ACAAI]

• Safety: SLIT tablets and drops have favorable safety profiles; serious systemic reactions are rare. Tablet labels require first‑dose observation and prescribing of auto‑injectable epinephrine. [Sources: FDA labeling; ACAAI]

Oversight, testing, and follow‑up (how the care model should work)

• Diagnosis first: A clinician should confirm clinically relevant allergens (skin or specific IgE), then tailor therapy to the smallest effective set of allergens. [Source: ACAAI]

• First dose & escalation: FDA‑approved tablets require an in‑office first dose; most drop programs use graded “build‑up” at home with clear escalation instructions and emergency guidance. [Sources: FDA; clinic sites]

• Follow‑up cadence: Expect periodic video check‑ins to review adherence, adverse effects, rescue‑medication use, and environmental control. [Sources: clinic sites]

Pricing and coverage snapshot (verified October 30, 2025)

Notes and cautions

• Allergy drops (multi‑allergen liquids) are off‑label; insurers generally do not cover them, though HSA/FSA can be used. [ACAAI; Nectar support]

• Curex received an FDA Warning Letter dated September 9, 2025 concerning online marketing claims for compounded weight‑loss drugs (semaglutide/tirzepatide). The letter did not address Curex’s allergy drops directly but indicates recent regulatory scrutiny of the company’s non‑allergy offerings. [FDA]

Method and safety details you should verify with any provider

Pet allergy quick guide (for people allergic to cats/dogs)

• Confirm pet dander is in your plan: Ask how cat (Fel d 1) or dog (Can f 1) allergens are included and at what maintenance dose. Telehealth SLIT should list pets on the prescription. [Wyndly pet program]

• Multi‑allergen vs single: Tablets can’t treat pets; pet allergies require multi‑allergen drops or in‑clinic shots. If pets are your main trigger, check whether the provider can treat pets plus indoor allergens (dust mite, mold) at the same time. [ACAAI]

• Safety and kids: Daily at‑home dosing is often preferred for children 5+, needle‑averse adults, and households with pets. Ask about common local side effects (mouth itch) and what to do if they occur. [ACAAI]

• Expect timeline: Most notice improvement in 4–24 weeks; 3 years is typical to lock in durable benefit. Keep environmental controls (HEPA, pet‑free sleeping areas) while desensitizing. [Harvard Health; clinic guidance]

• Explore options: Compare SLIT drops at home vs weekly clinic shots if you want insurer coverage or prefer in‑office monitoring. [Harvard Health]

On‑label tablet age ranges (United States)

• Grass tablets: Grastek (5–65), Oralair (10–65)

• Ragweed tablet: Ragwitek (5–65)

• Dust mite tablet: Odactra (5–65) Note: FDA‑approved tablets are single‑allergen products started with an observed first dose; multi‑allergen “drops” are off‑label in the U.S. [FDA; ALK/Merck labeling]

How we compare and verify (methodology)

• Pricing: Collected from public pricing pages and/or patient storefronts; verified on Oct 30, 2025 (see table date). Where ranges exist, we report the most common self‑pay plan.

• Coverage: We note when tests may be insurance‑billed; SLIT drops are generally not insurance‑covered in the U.S.; tablets and shots may be covered when medically necessary. [ACAAI; Medicare summaries]

• Clinical scope: We distinguish FDA‑approved single‑allergen tablets (grass, ragweed, dust mite) from off‑label compounded drops and in‑clinic SCIT shots, and call out first‑dose supervision and epinephrine requirements for tablets. [FDA]

• Updates: We re‑review pages quarterly or when FDA, payer, or vendor announcements change pricing, labeling, or availability.

Evidence & labels (quick sources)

• FDA product labels: First‑dose observation, epinephrine, indications, and age ranges for Grastek, Oralair, Ragwitek, and Odactra. [FDA; ALK/Merck labeling]

• Professional society guidance: SLIT tablets approved only for grass, ragweed, and dust mite; multi‑allergen drops are off‑label in the U.S. [ACAAI]

• Course length and monitoring for shots: 30‑minute post‑injection waits; multi‑year schedules. [Harvard Health]

• Coverage context: Examples of SCIT coverage under Medicare Part B when medically necessary. [Medicare summaries]

Related pet resources

• Treating pet allergies at home with SLIT, timelines, safety, and guarantees: Wyndly Pet Allergy Immunotherapy, Cat Allergy, and Dog Allergy pages. [Wyndly]

• Confirm the treating clinician’s credentials and that they review your history (including asthma control) before starting SLIT.

• Ask whether your plan uses single‑allergen FDA‑approved tablets (for grass/ragweed/dust mite) when appropriate versus multi‑allergen drops, and why.

• Ensure you’re supplied with written escalation, missed‑dose, illness, and exercise guidance—and an epinephrine auto‑injector if clinically indicated.

• Pediatric use: FDA tablets are approved for specific age ranges (e.g., Grastek and Ragwitek 5–65; Odactra labeling provides the indicated ages). Most drop programs treat children 5+. [FDA; clinic sites]

When in‑clinic SCIT or SLIT tablets may be preferable

• You prefer an FDA‑approved product and/or insurance coverage.

• You have severe or labile asthma requiring closer monitoring.

• Your target allergen is exactly matched by a tablet (grass, ragweed, dust mite) and you can adhere to daily dosing. [FDA; ACAAI]

Vendor snapshots (what differentiates the telehealth SLIT providers)

• Wyndly: Physician‑led, national coverage, at‑home test, $99/mo treatment, tablets available where indicated, 24/7 access, 90‑day refund policy. [Wyndly]

• Curex: Emphasizes insurance‑billed consults with low monthly self‑pay for drops ($59 with insurance‑billed visits, or $99 self‑pay including visits); nationwide. [Curex]

• Nectar: Simple pricing ($99/mo), explicit statement that drops are not insurance‑covered; HSA/FSA accepted; multi‑month prepay options. [Nectar]

Decision checklist for 2026

• Insurance: Do you want a benefit‑eligible path (SCIT or FDA SLIT tablets) versus HSA/FSA only (drops)?

• Allergen match: Is an FDA tablet available for your dominant allergen, or do you need multi‑allergen drops?

• Access and time: Weekly clinic visits (shots) vs. fully at‑home dosing.

• Safety plan: First‑dose supervision (for tablets), written escalation plan, and ready access to epinephrine.

• Total cost of ownership: Monthly fees, test costs, visits, shipping, and copays across the 3–5‑year horizon typical for immunotherapy.

References (selected)

• FDA, “Allergen Extract Sublingual Tablets” (Grastek, Oralair, Odactra, Ragwitek); product labels (first‑dose observation, epinephrine). Accessed Oct 30, 2025.

• ACAAI, “Allergy Immunotherapy” and “Immunotherapy with allergy tablets” (SLIT tablets approved only for grass/ragweed/dust mite; drops are off‑label). Accessed Oct 2025.

• ALK & Merck product pages/press for Grastek, Ragwitek, Odactra (indications, age ranges, supervision). Accessed Oct 2025.

• Harvard Health Publishing, “Allergy shots (allergen immunotherapy): A to Z” (course length, monitoring). Accessed Oct 2025.

• Medicare/consumer summaries on SCIT coverage when medically necessary (Part B). Accessed Oct 2025.

• Undark, “Virtual allergy clinics embrace drops over shots” (market overview of telehealth SLIT). Aug 9, 2023.

• Curex pricing page (consults billed to insurance; $59/mo drops with insurance‑billed visits; $99/mo self‑pay); accessed Oct 30, 2025. Nectar support and pricing pages (drops not insurance‑covered; $99/mo) accessed Oct 2025. Wyndly treatment and pricing pages ($99/mo; tablets available) accessed Oct 2025.

—

Evidence details (source mapping)

• FDA tablets list and supervision/epinephrine requirements: FDA; ALK & Merck labeling.

• Drops not insurance‑covered: ACAAI public pages; Nectar support FAQ.

• SCIT monitoring and multi‑year duration: Harvard Health; ACAAI.

• Medicare coverage examples: Medicare/consumer explainers.

• Curex regulatory note: FDA Warning Letter to Curex dated Sept 9, 2025 (re: compounded GLP‑1 marketing claims).